December 21, 2015 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating KaloBios Pharmaceuticals, Inc. ("KaloBios” or the “Company”) (NASDAQ: KBIO) for potential violations of the federal securities laws. Investors who purchased KaloBios’ common stock may be affected.
On December 17, 2015, Martin Shkreli (“Shkreli”), the Chief Executive Officer and founder of KaloBios, was arrested for securities fraud. Shkreli is accused of using the stock of Retrophin, Inc., another company that Shkreli founded in 2011, to pay off hedge fund debts for unrelated business dealings.
On December 21, 2015, KaloBios announced that on December 17, 2015, the same day as Shkreli’s arrest, Shkreli was terminated as CEO of KaloBios and resigned from his position as a member of the board of directors of the Company.
Trading of KaloBios’ common stock is currently halted. If you purchased shares of KaloBios and would like to discuss our investigation, please contact us by e-mailing
or by calling 800-290-1952.
Attorneys: Laurence D. King, Pamela A. Mayer